Clinical Trial Update: Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating JS207 for advanced non-small cell lung cancer after progression on platinum-based chemotherapy and immunotherapy; currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JS207

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Advanced NSCLC | Phase 2 | Status: RECRUITING